- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502199
Dysautonomic Phenotype in Male Patients With MECP2 Mutation (MECP2BOYS)
Dysautonomic Signs Among MECP2boys
Study Overview
Status
Intervention / Treatment
Detailed Description
First, we will launch a national call for participation in all the genetics departments in France to research boys with a missense or a non-sens mutation in the MECP2 gene. Our inclusion criteria is : less than 16 years old or dead before 16 years old patients of masculin sex with a missense or non-sens mutation in the MECP2 gene. Exclusion criteria is : patient under judicial protection or participation refusal by one of the legal guardian. Inclusion will take place in August 2020.
We had conceived an excel spreadsheet (2007 version) to collect all the datas needed with general data such as age, genetic mutation with the HGVS nomenclature using the NM_001110792.2, familial and personal history, mensurations, dysmorphic signs. To search dysautonomic signs, we used a system approach. We will look for neurological signs : abnormal movements, sleep disturbance, cardiologic signs :abnormal bradycardia or tachycardia, hypotension, rythms anomalies, respiratory signs : respiratory irregularities, apnea, hyperpnea , digestive signs : gastrooesophagal reflux, constipation, diarrhea, vomiting or subocclusif episodes, thermoregulation signs : abnormal hypo or hyperthermia, excessive sweating. Each time a dysautonomic sign will be reported in a letter of a patient, we will demand this sign to be objectived by a complementary exam, or by a precise device during an hospitalisation : electoencephalogram (EEG), polysomnography (PSG), Electrocardiogram (ECG), holter-ECG, digestive fibroscopies, scoped surveillance.
If we have a positive response, we will contact the main caregiver of the patient who can be a neurologist or a geneticist and will provid him a spreadsheet and an explanatory sheet. We will ask of him a systematic review of all the letters of the patient including letters of hospitalisation, of the specialists, complementary exams. A non-opposition letter will be sent to him in a way he can send it to the legal guardians of the children : a non-opposition of 15 days will be requested. Then, the filled spreadsheet will be sent back to the center of inclusion in Brest through a securised mailbox. Data will be kept on a secure database with a password.
Our primary endpoint is the presence of at least one dysautonomic sign. We intend to include between 10 and 20 patients in this multicentric study. To analyse our results, we will use a descriptive approach.
This protocole was validated by the Ethic Comitee of Brest in june 18, 2020
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Juliette ROPARS
- Phone Number: 0298223657
- Email: juliette.ropars@chu-brest.fr
Study Locations
-
-
-
Besançon, France
- CHU de Besancon
-
Contact:
- DELPLANCQ DELPLANCQ
-
Brest, France, 29609
- CHRU de Brest
-
Lille, France
- CHRU de Lille
-
Contact:
- PETIT PETIT
- Email: Florence.petit@chru-lille.fr
-
Lyon, France
- Hospices Civiles de Lyon
-
Contact:
- Gaetan LESCA,
- Email: gaetan.lesca@chu-lyon.fr
-
Sub-Investigator:
- Vincent DESPORTES
-
Sub-Investigator:
- Dorothée VILLE
-
Marseille, France
- Hopital De La Timone
-
Contact:
- Mathieu MILH
-
Nimes, France
- CHU de NIMES
-
Contact:
- Marie FARMER,
-
Paris, France
- Hôpital Robert Debré
-
Contact:
- Catherine SARRET
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:less than 16 years old or dead before 16 years old patients of masculin sex with a missense or non-sens mutation in the MECP2 gene -
Exclusion Criteria:patient under judicial protection or participation refusal by one of the legal guardian
-
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
presence of at least one dysautonomic sign
Time Frame: one month
|
one month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Brain Diseases
- Rett Syndrome
- Primary Dysautonomias
- Autonomic Nervous System Diseases
Other Study ID Numbers
- MECP2BOYS (29BRC20.0182)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysautonomia
-
NYU Langone HealthNot yet recruitingFamilial DysautonomiaUnited States
-
NYU Langone HealthNot yet recruiting
-
NYU Langone HealthCompletedFamilial DysautonomiaUnited States
-
NYU Langone HealthCompletedFamilial DysautonomiaUnited States
-
NYU Langone HealthCompletedFamilial DysautonomiaUnited States
-
NYU Langone HealthRecruitingHereditary Sensory and Autonomic Neuropathies | Familial Dysautonomia (Riley-Day Syndrome) | Hereditary Sensory and Autonomic Neuropathy 3United States, Israel
-
St Carlos Hospital, Madrid, SpainRecruitingHypertension | Blood Pressure Disorders | Renal Denervation | Blood Pressure Variability | Increased Variability | Sympathetic DysautonomiaSpain
-
NYU Langone HealthWithdrawnFamilial DysautonomiaUnited States
-
NYU Langone HealthWithdrawnNausea | Vomiting | Familial DysautonomiaUnited States
-
NYU Langone HealthCompletedFamilial Dysautonomia
Clinical Trials on non interventional study
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
University Hospital, RouenRecruitingDyspepsia | Irritable Bowel Syndrome | Functional Constipation | Faecal IncontinenceFrance
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Mayo ClinicRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
Mayo ClinicRecruitingClear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal TumorUnited States
-
Mayo ClinicRecruitingProstate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Institute for Biomedical Imaging...RecruitingProstate NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
Mayo ClinicRecruitingBreast CarcinomaUnited States